专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2004050855A2 RAPID ONE-STEP METHOD FOR GENERATION OF ANTIGEN LOADED DENDRITIC CELL VACCINE FROM PRECURSORS 审中-公开
标题翻译：用于从前体产生抗原负载的细胞真菌的快速一步法
公开(公告)号：WO2004050855A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/038553
申请日：2003-12-04
申请人： BAYLOR RESEARCH INSTITUTE , BANCHEREAU, Jacques, F. , PALUCKA, Anna, K.
发明人： BANCHEREAU, Jacques, F. , PALUCKA, Anna, K.
IPC分类号： C12N
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/5154 , C12N5/0639 , C12N2501/22 , C12N2501/25
摘要： A one-step method for producing antigen loaded antigen-presenting cells from monocytes ex vivo has been found which comprises contacting the monocytes with a composition comprising an activator such as TNF alpha preferably in combination with at least one growth factor such as GM-CSF and at least one soluble or particulate antigen. According to the methods of the present invention, antigen-loaded dendritic cell vaccines can be generated within as little as three (3) days. In another method of the present invention, antigen loaded antigen-presenting cells are produced from monocytes ex vivo by contacting the monocytes with TNF alpha and granulocyte-macrophage colony stimulating factor at one time point to form antigen-presenting cells and then contacting antigenpresenting cells with soluble or particulate antigenic material at a second time point to form antigen loaded antigen-presenting cells, wherein the antigen loaded antigen-presenting cells are produced in less than four days. The present invention also includes a vaccine which comprises monocyte-derived antigen loaded antigen-presenting cells, wherein the antigenpresenting cells are composed of two or more subsets selected from the group consisting of Langerhans cells with surface markers (CD 1 a+ CD207+); interstitial dendritic cells with surface markers (CD 1a+ CD207-); double negative dendritic cells with surface markers 20 (CD 1 a-CD 14-); and dendritic cells with surface markers (CD 14+ CD 1 a- CD209+).
摘要翻译：已经发现从体外从单核细胞产生抗原负载抗原呈递细胞的一步法包括使单核细胞与包含活化剂如TNFα的组合物接触，优选与至少一种生长因子如GM-CSF和至少一种可溶或微粒抗原。根据本发明的方法，可以在短短三（3）天内产生抗原负载的树突状细胞疫苗。在本发明的另一种方法中，抗原呈递细胞由单核细胞通过单核细胞与TNFα和粒细胞 - 巨噬细胞集落刺激因子在一个时间点接触形成抗原呈递细胞，然后将抗原呈递细胞与可溶性或微粒状抗原物质，以形成抗原负载的抗原呈递细胞，其中抗原呈递细胞在不到四天内产生。本发明还包括一种疫苗，其包含单核细胞衍生的抗原负载抗原呈递细胞，其中所述抗原呈递细胞由两个或更多个选自具有表面标记的朗格汉斯细胞（CD1a + CD207 +）的子集组成; 具有表面标志物的间质树突状细胞（CD 1a + CD207-）; 具有表面标记20的双负性树突状细胞（CD 1 a-CD 14-）; 和具有表面标志物的树突状细胞（CD14 + CD11a-CD209 +）。

32. 发明申请

WO2003083044A2 TISSUE ANALOGS FOR IN VITRO TESTING AND METHOD OF USE THEREFOR 审中-公开
标题翻译：用于体外测试的组织模拟及其使用方法
公开(公告)号：WO2003083044A2
公开(公告)日：2003-10-09
申请号：PCT/US2003/010105
申请日：2003-03-21
申请人： CONDROS, INC. , JOHNS HOPKINS UNIVERSITY , FRONDOZA, Carmelita, G. , FINK, David, J.
发明人： FRONDOZA, Carmelita, G. , FINK, David, J.
IPC分类号： C12N
CPC分类号： C12N5/0697 , C12N5/0655 , C12N2501/23 , C12N2501/25 , C12N2503/04 , C12N2531/00 , G01N33/5082
摘要： A test system and method are disclosed for using tissue analogs The method includes the following steps: (1) isolating the cells to be implanted from donor tissue; (2) seeding the cells onto a particulate microcarrier bead; (3) culturing the cells on the microcarriers to achieve an expansion in the number of cells; and (4) further culturing the cell-particle aggregates to form a tissue analog. The resulting tissue analog and test system may be used for use in screening drugs for diseases and pathological conditions, for testing for toxicity of chemical agents, or for genomic or proteomic screening. The tissue analogs may also be subjected to conditions that will induce disease-like conditions such that the resulting diseased tissue analogs may be used to screen for therapeutic drugs that modify the diseased tissue analog physiology or block progression of the diseased conditions. Kits may be developed for the purpose of conducting multiple tests in conventional multi-well plate systems.
摘要翻译：公开了使用组织类似物的测试系统和方法。该方法包括以下步骤：（1）从供体组织中分离待植入的细胞; （2）将细胞接种到微粒载体珠粒上; （3）在微载体上培养细胞以实现细胞数量的扩大; 和（4）进一步培养细胞 - 颗粒聚集体以形成组织类似物。所得到的组织类似物和测试系统可用于筛选用于疾病和病理状况的药物，用于测试化学试剂的毒性，或用于基因组或蛋白质组学筛选。组织类似物还可以经受将引起疾病状况的条件，使得所得到的患病组织类似物可用于筛选改变患病组织的类似生理学或阻断疾病状态进展的治疗药物。可以开发用于在常规多孔板系统中进行多次测试的试剂盒。

33. 发明申请

WO2003023023A1 HERSTELLUNG UND VERWENDUNG VON HUMANEN CD124 UND CD116 POSITIVEN TUMORZELLLINIEN ZUR HERSTELLUNG VON ALLOGENEN ODER SEMI-ALLOGENEN IMMUNTHERAPEUTIKA 审中-公开
标题翻译：生产和人类和CD124 CD116阳性肿瘤细胞系的异体或半异体免疫疗法的生产中使用
公开(公告)号：WO2003023023A1
公开(公告)日：2003-03-20
申请号：PCT/EP2002/009260
申请日：2002-08-19
申请人： NEMOD IMMUNTHERAPIE AG , GOLETZ, Steffen , SCHEPER, Rik, J. , MASTERSON, Alan , PINEDO, Herbert, M.
发明人： GOLETZ, Steffen , SCHEPER, Rik, J. , MASTERSON, Alan , PINEDO, Herbert, M.
IPC分类号： C12N5/08
CPC分类号： C12N5/0694 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , C12N5/0639 , C12N2501/15 , C12N2501/22 , C12N2501/24 , C12N2501/25 , C12N2501/39 , C12N2510/00
摘要： Es wird ein Verfahren zur Herstellung und Verwendung von CD124+ und CD116+ Zelllinien zur Herstellung von effektiven dendritischen Zellen (DC) mit Hilfe von stimulatorischen Molekülen vorgeschlagen.
摘要翻译：它是由刺激分子的手段提出了用于生产有效的树突状细胞（DC）的制备和使用的CD124 +和CD116 +的细胞系的方法。

34. 发明申请

WO0185920A2 COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-PRESENTING CELLS 审中-公开
标题翻译：用于生产抗原细胞的组合物和方法
公开(公告)号：WO0185920A2
公开(公告)日：2001-11-15
申请号：PCT/US0115300
申请日：2001-05-11
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , MOHAMADZADEH MANSOUR , PALUCKA ANNA KAROLINA
发明人： BANCHEREAU JACQUES F , MOHAMADZADEH MANSOUR , PALUCKA ANNA KAROLINA
IPC分类号： A61K38/20 , A61K38/21 , C12N5/0784 , C12N5/06 , A61K35/12 , C07K14/54 , C12N1/38
CPC分类号： C12N5/0639 , A61K2039/5154 , C12N2501/052 , C12N2501/056 , C12N2501/15 , C12N2501/22 , C12N2501/23 , C12N2501/25 , C12N2501/52
摘要： The present invention relates to compositions and methods for producing antigen-presenting cells, in vitro, ex vivo or in vivo. This invention relates more particularly to methods and compositions for producing dendritic cells using interleukin-15, preferably in combination with a growth factor such as Granulocyte-Macrophage colony stimulating factor. This invention is particularly suited for producing immature dendritic cells and activated cells from precursors, in vitro, ex vivo or in vivo. The invention also relates to compositions for implementing these methods, as well as compositions comprising antigen-presenting cells and uses thereof. Dendritic cells or membrane vesicles derived therefrom have utility in many applications, including diagnostic, therapy, vaccination, research, screening and gene delivery.
摘要翻译：本发明涉及在体外，离体或体内产生抗原呈递细胞的组合物和方法。本发明更具体地涉及使用白介素-15生产树突状细胞的方法和组合物，优选与生长因子如粒细胞 - 巨噬细胞集落刺激因子组合。本发明特别适用于从体外，离体或体内从前体生产未成熟树突细胞和活化细胞。本发明还涉及用于实施这些方法的组合物，以及包含抗原呈递细胞的组合物及其用途。衍生自其的树突状细胞或膜泡囊可用于许多应用，包括诊断，治疗，疫苗接种，研究，筛选和基因递送。

35. 发明申请

WO01085193A2 METHOD FOR PROMOTING NEOVASCULARIZATION 审中-公开
标题翻译：促进新生血管的方法
公开(公告)号：WO01085193A2
公开(公告)日：2001-11-15
申请号：PCT/US2001/014545
申请日：2001-05-07
IPC分类号： A61K38/18 , A61K38/19 , A61K38/22 , A61K45/00 , A61K45/06 , A61P1/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P9/14 , A61P17/02 , A61P41/00 , A61P43/00 , C12N5/071 , A61K38/00
CPC分类号： C12N5/069 , A61K38/177 , A61K38/1825 , A61K45/06 , C12N2501/115 , C12N2501/165 , C12N2501/25 , C12N2501/998 , A61K2300/00
摘要： The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.
摘要翻译：本发明涉及一种用于增强血管生成活性以促进新血管形成的方法，包括向受试者施用包含协同有效量的TWEAK激动剂和血管发生因子的制剂。

36. 发明申请

WO0001823A3 FLT3-L MUTANTS AND METHODS OF USE 审中-公开
标题翻译： FLT3-L突变体及其使用方法
公开(公告)号：WO0001823A3
公开(公告)日：2000-08-03
申请号：PCT/US9914296
申请日：1999-06-25
申请人： IMMUNEX CORP
发明人： GRADDIS THOMAS J , MCGREW JEFFREY T
IPC分类号： A61K38/00 , A61K39/39 , C07K14/52 , C12N5/0784 , C12N15/10 , C12N15/19 , A61K38/19 , C07K19/00
CPC分类号： C07K14/52 , A61K38/00 , A61K39/39 , A61K2039/55516 , C07K2319/00 , C12N5/0639 , C12N15/102 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/25 , C12N2501/26
摘要： A screening method for identifying mutant polypeptides having at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction is disclosed. Also disclosed are mutant polypeptides of the hematopoietic growth factor flt3-Ligand (flt3-L) identified using this method, nucleic acids encoding these flt3-L mutant polypeptides, and methods of treatment involving in vitro and in vivo use of the mutant polypeptides and nucleic acids.
摘要翻译：公开了一种用于鉴定与涉及受体 - 配体相互作用的野生型蛋白质具有至少一个氨基酸差异的突变体多肽的筛选方法。还公开了使用该方法鉴定的造血生长因子flt3-配体（flt3-L）的突变多肽，编码这些flt3-L突变体多肽的核酸以及涉及突变多肽和核酸的体外和体内使用的治疗方法酸。

37. 发明申请

WO1998006823A2 CYTOKINE-FREE CULTURE OF DENDRITIC CELLS 审中-公开
标题翻译：小细胞细胞无细胞无血清培养
公开(公告)号：WO1998006823A2
公开(公告)日：1998-02-19
申请号：PCT/US1997013759
申请日：1997-08-13
申请人： BAXTER INTERNATIONAL INC.
发明人： BAXTER INTERNATIONAL INC. , VACHULA, Mona , VAN EPPS, Dennis, E. , ALZONA, Mortimer, T. , AONO, Frederick, M.
IPC分类号： C12N05/06
CPC分类号： C12N5/0636 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2500/05 , C12N2500/14 , C12N2500/36 , C12N2500/38 , C12N2501/01 , C12N2501/02 , C12N2501/125 , C12N2501/22 , C12N2501/25 , C12N2501/515
摘要： A method for producing human dendritic cells for therapeutic purposes which allows culture-deriving dendritic cells using no cytokines, or reduced cytokines. The method involves culturing mononuclear cells from blood or bone marrow in a medium containing at least one agent such as a calcium ionophore, e.g. A23187, theophylline, protaglandin E1, dibutyryl cyclic AMP, Vitamin D3, Vitamin E, retinoic acid, or a fatty acid. The culture is maintained for a sufficient time, typically 4 - 14 days, to produce a culture enriched for dendritic cells, as evidenced by at least about 2.5 % of total cells exhibiting dendritic cell processes, or a dendritic cell antigen such as CD80, CD86, or CD1a. Also provided is a method to produce antigen-specific human T-cells by pulsing the dendritic cells obtained by the method of the invention with an antigen such as a viral, tumor, bacterial, or cell surface antigen, and then co-culturing T-cells with the antigen-pulsed dendritic cells. Useful for treatment of viral or bacterial infections, useful as a cancer vaccine, useful to induce tolerance of allo- or xeno-graft.
摘要翻译：本发明涉及一种生产用于治疗目的从培养物，而不细胞因子或具有很少的细胞因子的人树突状细胞的方法。所述方法包括在含有至少一种剂的培养基中培养的血液或骨髓单核细胞，例如：钙离子载体（例如，A23187），茶碱，前列腺素E1，二丁酰基环AMP ，维生素D3，维生素E，视黄酸或脂肪酸。将培养物维持足够长的时间，例如，4至14天，为生产具有的树突状细胞过程中总细胞的树突状细胞中富集至少2.5％，或细胞抗原树突如CD80，CD86或CD1a。本发明还涉及一种方法，用于生产抗原，其包括使用病毒抗原，细菌或肿瘤或细胞表面脉动通过上述方法获得的树突状细胞的特异性的人T细胞然后共同培养T细胞和抗原性冲动树突状细胞。由此获得的树突状细胞是病毒或细菌感染的治疗中是有用的，作为针对癌症的疫苗或用于感应耐受性异体或异种移植。

38. 发明申请

WO1995034676A1 POPULATION OF CELLS ENRICHED FOR MYELOID AND/OR LYMPHOID PROGENITORS AND METHODS OF MAKING AND USING 审中-公开
标题翻译：对于麦芽糖和/或淋巴细胞产生的细胞的繁殖和制备和使用的方法
公开(公告)号：WO1995034676A1
公开(公告)日：1995-12-21
申请号：PCT/US1995003038
申请日：1995-03-09
申请人： SYSTEMIX, INC. , GALY, Anne, H., M. , MULE, James, J.
发明人： SYSTEMIX, INC.
IPC分类号： C12Q01/00
CPC分类号： G01N33/56977 , A61K2035/124 , A61K2039/5154 , C12N5/0647 , C12N2501/125 , C12N2501/14 , C12N2501/145 , C12N2501/22 , C12N2501/2303 , C12N2501/2306 , C12N2501/235 , C12N2501/25 , C12N2501/26 , C12N2501/33 , C12N2502/1394 , C12N2510/00 , G01N33/56972
摘要： The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.
摘要翻译：本发明涉及基于细胞特异性标记物富集骨髓和/或淋巴祖细胞的造血细胞群的方法。这些方法还提供了缺乏长期造血重建潜力的丰富的前胸淋巴细胞定居祖细胞群。由本发明提供的富含细胞和细胞群的组合物也由本发明提供。还包括细胞的使用方法。提供遗传修饰细胞的方法，就像从其获得的细胞一样。

39. 发明申请

WO1993020185A1 METHOD FOR IN VITRO PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS 审中-公开
标题翻译：树突细胞体外增殖的方法及其产生免疫原的用途
公开(公告)号：WO1993020185A1
公开(公告)日：1993-10-14
申请号：PCT/US1993003141
申请日：1993-04-01
申请人： STEINMAN, Ralph, M. , INABA, Kayo , SCHULER, Gerold
IPC分类号： C12N05/00
CPC分类号： A61K39/0008 , A61K2035/122 , A61K2039/5154 , C12N5/0639 , C12N2501/22 , C12N2501/23 , C12N2501/25
摘要： A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.
摘要翻译：提供了一种用于产生树突状细胞前体的增殖培养物的方法。还提供了从增殖型树突状细胞前体在培养物中产生成熟树突状细胞的方法。成熟树突细胞的培养提供了产生由树突状细胞修饰抗原或用抗原脉冲的树突状细胞的新型T细胞依赖性抗原的有效手段，包括微粒，该抗原在抗原活化的树突状细胞上被加工和表达。本发明的新型抗原可以用作疫苗的免疫原或用于治疗疾病。这些抗原也可用于治疗自身免疫性疾病，例如幼年型糖尿病和多发性硬化症。

40. 发明申请

WO2017079673A1 GENOMIC ENGINEERING OF PLURIPOTENT CELLS 审中-公开
标题翻译：多功能细胞的基因组工程
公开(公告)号：WO2017079673A1
公开(公告)日：2017-05-11
申请号：PCT/US2016/060699
申请日：2016-11-04
申请人： FATE THERAPEUTICS, INC.
发明人： VALAMEHR, Bahram , ABUJAROUR, Ramzey , LEE, Tom Tong , LAN, Weijie , CLARKE, Raedun , BJORDAHL, Ryan
IPC分类号： C12N15/85 , C12N5/074
CPC分类号： C12N15/11 , A61K35/17 , C07K14/70503 , C07K14/7051 , C12N5/0696 , C12N9/22 , C12N15/1138 , C12N15/85 , C12N15/90 , C12N15/907 , C12N2310/20 , C12N2501/25 , C12N2501/505 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2501/998 , C12N2510/00 , C12N2800/80 , C12N2830/00
摘要： Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
摘要翻译：提供用于获得基因组工程化iPSC的方法和组合物，以及在选定位点具有稳定和功能性基因组编辑的衍生细胞。还提供了源自基因组工程化iPSC的细胞群体或克隆细胞系，其包含一种或多种外源多核苷酸的靶向整合和/或一种或多种选择的内源性基因中的/或寡核苷酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式